These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30955110)

  • 1. Delay in initiation of postoperative adjuvant chemotherapy with S-1 monotherapy and prognosis for gastric cancer patients: analysis of a multi-institutional dataset.
    Nakanishi K; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
    Gastric Cancer; 2019 Nov; 22(6):1215-1225. PubMed ID: 30955110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing and site-specific trends of recurrence in patients with pathological stage II or III gastric cancer after curative gastrectomy followed by adjuvant S-1 monotherapy.
    Takahashi R; Ohashi M; Kano Y; Ida S; Kumagai K; Nunobe S; Chin K; Yamaguchi K; Nagino M; Sano T; Hiki N
    Gastric Cancer; 2019 Nov; 22(6):1256-1262. PubMed ID: 30877407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to initiation or duration of S-1 adjuvant chemotherapy; which really impacts on survival in stage II and III gastric cancer?
    Fujitani K; Kurokawa Y; Takeno A; Endoh S; Ohmori T; Fujita J; Yamasaki M; Takiguchi S; Mori M; Doki Y;
    Gastric Cancer; 2018 May; 21(3):446-452. PubMed ID: 28965205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer.
    Mori M; Shuto K; Kosugi C; Narushima K; Hayashi H; Matsubara H; Koda K
    BMC Cancer; 2018 Dec; 18(1):1261. PubMed ID: 30558575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer: a randomized controlled trial.
    Tatebe S; Tsujitani S; Nakamura S; Shimizu T; Yamane N; Nishidoi H; Kurisu Y; Kanayama H; Ogawa H; Ikeguchi M
    Gastric Cancer; 2014; 17(3):508-13. PubMed ID: 23948997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
    Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
    Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience.
    Yen HH; Chen CN; Yeh CC; Lai IR
    World J Surg Oncol; 2021 Apr; 19(1):124. PubMed ID: 33865416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
    Ito S; Ohashi Y; Sasako M
    BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor size  ≥50 mm as an Independent Prognostic Factor for Patients with Stage II or III Gastric Cancer After Postoperative S-1 Monotherapy: Analysis of a Multi-institution Dataset.
    Tsutsuyama M; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
    World J Surg; 2020 Jan; 44(1):194-201. PubMed ID: 31552460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study.
    Mitani S; Kadowaki S; Hasegawa H; Wakatsuki T; Hara H; Tajika M; Nishikawa K; Hirao M; Takahari D; Chin K; Muro K
    Int J Clin Oncol; 2019 Oct; 24(10):1197-1203. PubMed ID: 31152323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
    Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
    Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facilitated completion of 1-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer by medical oncologists.
    Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Ida S; Kumagai K; Sano T; Nunobe S
    Surg Today; 2020 Oct; 50(10):1197-1205. PubMed ID: 32240378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC).
    Ueda Y; Fujimura T; Kinami S; Hirono Y; Yamaguchi A; Naitoh H; Tani T; Kaji M; Yamagishi H; Miwa K;
    Jpn J Clin Oncol; 2006 Aug; 36(8):519-22. PubMed ID: 16803844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Chemotherapy with S-1 plus Cisplatin for Patients with Stage III Gastric Cancer After Curative Resection.
    Mita K; Ito H; Ota E; Takahashi K; Hashimoto M; Asakawa H; Hayashi T; Fujino K
    Anticancer Res; 2017 Mar; 37(3):1329-1333. PubMed ID: 28314299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
    Jeong JH; Park SR; Ahn Y; Ryu MH; Ryoo BY; Kong SY; Yook JH; Yoo MW; Kim BS; Kim BS; Kang YK
    Gastric Cancer; 2017 Jan; 20(1):146-155. PubMed ID: 26715117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer.
    Yamamoto M; Sakaguchi Y; Kinjo N; Yamaguchi S; Egashira A; Minami K; Ikeda Y; Morita M; Toh Y; Okamura T
    Ann Surg Oncol; 2016 Feb; 23(2):546-51. PubMed ID: 26442923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR.
    Ito S; Kodera Y; Mochizuki Y; Kojima T; Nakanishi H; Yamamura Y
    World J Surg; 2010 Sep; 34(9):2083-9. PubMed ID: 20379713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma.
    Li B; Shen S; You S; Zhang G; Gao S; Shi X; Wang H; Yin X; Xu X; Guo S; Jin G
    BMC Cancer; 2021 May; 21(1):612. PubMed ID: 34034684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
    Cho JH; Lim JY; Cho JY
    PLoS One; 2017; 12(10):e0186362. PubMed ID: 29040299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.